



Republic of the Philippines
Department of Health
CENTRAL OFFICE BIDS AND AWARDS COMMITTEE

COBAC RESOLUTION NO. 2020-431-A
04 February 2021

**RECOMMENDING APPROVAL FOR THE AMENDMENT TO COBAC RESOLUTION NO. 2020-431
FOR THE PROCUREMENT OF HIV RAPID DIAGNOSTIC TEST-3 (FOR rHIVda RE-
CONFIRMATION)
IB NO. 2020-248**

WHEREAS, COBAC Resolution No. 2020-431 "Recommending Approval for the Award of Contract for the Procurement of HIV Rapid Diagnostic Test-3 (For rHIVda Re-Confirmation) under IB No. 2020-248", was approved, to wit:

Item No.	Description	Qty.	Unit	Total Bid Price (PhP)	Supplier
1	HIV Rapid Diagnostic Test-3 (For rHIVda Re-Confirmation)	16,340	test	18,791,000.00	Pharmastar International Trading Corporation (PITC)

WHEREAS, on 29 December 2020, PITC conformed the Notice of Award (NOA) for the above-cited project;

WHEREAS, on 29 January 2021, the Procurement Service-Contract Management Division submitted its document finding/ observation through electronic mail (email) informing the following findings:

Requirement/Condition	Findings
Duly accomplished and signed Bid form	There is a discrepancy between the bid price in words (Eighteen Million Seven Hundred Ninety-One Pesos) and bid price in figures (PhP18,791,000.00) amounting to PhP790,209.00.
Statement/List of all ongoing government and private contracts, including contracts awarded but not yet started, if any	The amount of projects are not reflected in the first column of the form.

WHEREAS, pursuant to Section 32.2.3 of 2016 Revised Implementing Rules and Regulations (IRR) of Republic Act (RA) 9184, "in case of discrepancies between bid prices in figures and in words, the latter shall prevail";

WHEREAS, on 01 February 2021, the said observation and submitted documents of PITC were presented to the Central Office Bids and Awards Committee (COBAC)-C. Upon review and deliberation, the Committee decided to inform PITC relative to the above-cited findings;

WHEREAS, Section 34.4 of the Revised IRR of RA 9184, the BAC determines the lowest calculated bidder and when it passes all the criteria for post-qualification, the BAC shall recommend to the Head of the Procuring Entity the award of the contract to the said bidder at its submitted price or its calculated bid price, whichever is lower;

WHEREAS, on the same date, COBAC-C issued a letter through e-mail to PITC relative to the above-cited findings;

WHEREAS, on 03 February 2021, PITC submitted its response and conformed to the lower bid price which is PhP18,000,791.00;

WHEREAS, on 04 February 2021, the above-cited documents were presented to COBAC-C during its 16th Regular Meeting. Upon review and deliberation, based on the response of PITC, the Committee considered the submitted Bid Price which is PhP18,000,791.00 which is more advantageous to the Government;

WHEREAS, in all instances, the Procuring Entity shall ensure the most advantageous to the Government. Thus, the COBAC will consider the submitted Bid Price which is PhP18,000,791.00 as the Lowest Calculated Responsive Bid;

NOW THEREFORE, in consideration of the above premises, the herein members of the COBAC-C **HEREBY RESOLVE** to recommend approval for the amendment of contract price awarded to **Pharmastar International Trading Corporation** determined as Lowest Calculated Responsive Bid for the item listed below with a Total Contract Price of **Eighteen Million Seven Hundred Ninety-One Philippine Pesos (PhP18,000,791.00)**:

Item Description	From	To
HIV Rapid Diagnostic Test-3 (For rHIVda Re-Confirmation)	PhP18,791,000.00	PhP18,000,791.00

Signed this FEB 18 day of 2021 2021 at the Department of Health, San Lazaro Compound, Sta. Cruz, Manila.


CENTRAL OFFICE BIDS AND AWARDS COMMITTEE (COBAC) - C


DAVID P. MASIADO JR., ME, MM
Regular Member



GLORIA J. BALBOA, MD, MHA, MPH, CEO VI, CESO III
Regular Member


FAITH F. ALBERTO, MD
Regular Member


ANGELINA A. DEL MUNDO, MA, CESO III
Vice-Chairperson


ROMEO A. ONG, MD
Assistant Secretary of Health
Chairperson

By Authority of the Secretary of Health:


NAPOLEON L. AREVALO, MD, MPH, CESO IV
Director IV
Disease Prevention and Control Bureau

FEB 19 2021